

Supplementary

Table S1 Response to ICI

Parameters	N (%)
CR	0
PR	23 (51.1)
SD	8 (17.8)
PD	10 (22.2)
NE	4 (8.9)

NE, not evaluated; CR complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Table S2 Response to ICI according to mRNA-based gene expression before therapy

Variables	Response (%)	No response (%)	P value
CD3			0.678
Low	52.6	47.4	
High	59.1	40.9	
CD8			0.228
Low	66.7	33.3	
High	47.8	52.2	
PD-1			0.567
Low	61.1	38.9	
High	52.2	47.8	
PD-L1			0.829
Low	57.9	42.1	
High	54.5	45.5	
CTLA-4			0.829
Low	57.9	42.1	
High	54.5	45.5	

Table S3 Response to ICI according to Δ gene ex-pression

Variables	Response (%)	No response (%)	P value
Δ CD3			0.021
Increase	72.7	27.3	
Decrease	36.8	63.2	
Δ CD8			0.043
Increase	71.4	28.6	
Decrease	40.0	60.0	
Δ PD-1			0.678
Increase	59.1	40.9	
Decrease	52.6	47.4	
Δ PD-L1			0.183
Increase	65.2	34.8	
Decrease	44.4	55.6	
Δ CTLA-4			0.951
Increase	56.5	43.5	
Decrease	55.6	44.4	

Δ , change in expression before and after start of immune-checkpoint inhibitor.




Figure S1 Interindividual changes from baseline in association to mPFS (above or below median) for (A) CD3 and (B) CD8.